Long noncoding RNA PVT1 promotes non-small cell lung cancer cell proliferation through epigenetically regulating LATS2 expression

Molecular Cancer Therapeutics

Volumn 15, Issue 5, 2016, Pages 1082-1094

  Wan, Li ^a,b   Sun, Ming ^b   Liu, Guo Jian ^a   Wei, Chen Chen ^a   Zhang, Er Bao ^b   Kong, Rong ^b   Xu, Tong Peng ^b   Huang, Ming De ^b   Wang, Zhao Xia ^a  

^a THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

LARGE TUMOR SUPPRESSOR KINASE 2; LONG UNTRANSLATED RNA; PROTEIN; PROTEIN MDM2; PROTEIN P53; RNA; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; LATS2 PROTEIN, HUMAN; PROTEIN BINDING; PROTEIN SERINE THREONINE KINASE; PVT1 LONG-NON-CODING RNA, HUMAN; TUMOR SUPPRESSOR PROTEIN;

A549 CELL LINE; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CARCINOGENESIS; CELL CYCLE ARREST; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ECTOPIC EXPRESSION; EPIGENETICS; FEMALE; GENE; GENE OVEREXPRESSION; GENE REPRESSION; GENE SILENCING; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; LATS2 GENE; LUNG CANCER CELL LINE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDIAN SURVIVAL TIME; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PVT1 GENE; REGULATORY MECHANISM; TUMOR VOLUME; AGED; ANIMAL; CANCER GRADING; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE CHECKPOINT; CELL SURVIVAL; CELL TRANSFORMATION; DISEASE MODEL; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; LUNG NEOPLASMS; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PROGNOSIS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TUMOR CELL LINE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANIMALS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; LUNG NEOPLASMS; MALE; MICE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-MDM2; RNA, LONG NONCODING; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84971377836     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0707     Document Type: Article

References (46)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90.
2. Pascal Séve, Tony Reiman, Charles Dumontet. The role of bIII tubulin in predicting chemoresistance in non-small cell lung cancer. Int J Clin Oncol 2013; 18:371-9.
3. Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L. Kunkler I; EUROCARE-4 Working Group. Recent cancer survival in Europe: A 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 2007; 8:784-96.
4. Sarah D, Carrie AD, AngelikaM, Alex D, Timo L, Ali MM, et al. Landscape of transcription in human cells. Nature 2012; 489; 101-8.
5. Nagano T, Fraser P. No-nonsense functions for long noncoding RNAs. Cell 2011; 145:178-81.
6. Spizzo R, Almeida MI, Colombatti A, Calin GA. Long non-coding RNAs and cancer: A new frontier of translational research?Oncogene 2012; 31: 4577-87.
7. Liu JY, Yao J, Li XM, Song YC, Wang XQ, Li YJ, et al. Pathogenic role of lncRNA-MALAT1 in endothelial cell dysfunction in diabetes mellitus. Cell Death Dis 2014; 5:e1506.
8. Ounzain S, Pezzuto I, Micheletti R, Burdet F, Sheta R, Nemir M, et al. Pedrazzini functional importance of cardiac enhancer-associated noncoding RNAs in heart development and disease. J Mol Cell Cardiol 2014; 76:55-70.
9. Xu TP, Huang MD, Xia R, Liu XX, Sun M, Yin L, et al. Decreased expression of the long non-coding RNA FENDRR is associated with poor prognosis in gastric cancer and FENDRR regulates gastric cancer cell metastasis by affecting fibronectin expression. J Hematol Oncol 2014; 7:63.
10. Vikram R, Ramachandran R, Abdul KS. Functional significance of long noncoding RNAs in breast cancer. Breast Cancer 2014; 21:515-21.
11. Cheng N, Li X, Zhao C, Ren S, Chen X, Cai W, et al. Microarray expression profile of long non-coding RNAs in EGFR-TKIs resistance of human nonsmall cell lung cancer. Oncol Rep 2015; 33:833-9.
12. Tong YS, Wang XW, Zhou XL, Liu ZH, Yang TX, Shi WH, et al. Identification of the long non-coding RNA POU3F3 in plasma as a novel biomarker for diagnosis of esophageal squamous cell carcinoma. Mol Cancer 2015; 14:3.
13. Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell 2007; 129:1311-23.
14. Khalil AM, Guttman M, Huarte M, GarberM, Raj A, Rivea Morales D, et al. Many human large intergenic noncoding RNAs associate with chromatinmodifying complexes and affect gene expression. Proc Natl Acad Sci U S A 2009; 106:11667-72.
15. Beckedorff FC, Ayupe AC, Crocci-Souza R, Amaral MS, Nakaya HI, Soltys DT, et al. The intronic long noncodingRNAANRASSF1 recruits PRC2 to the RASSF1A Promoter, reducing the expression of RASSF1A and increasing cell proliferation. PLoS Genet 2013; 9:e1003705.
16. He W, Cai Q, Sun F, Zhong G, Wang P, Liu H, et al. Linc-UBC1 physically associates with polycomb repressive complex 2 (PRC2) and acts as a negative prognostic factor for lymph node metastasis and survival in bladder cancer. Biochim Biophys Acta 2013; 1832:1528-37.
17. Tseng YY, Moriarity BS, Gong W, Akiyama R, Tiwari A, Kawakami H, et al. PVT1 dependence in cancer with MYC copy-number increase. Nature 2014; 512:82-6.
18. Takahashi Y, Sawada G, Kurashige J, Uchi R, Matsumura T, Ueo H, et al. Amplification of PVT-1 is involved in poor prognosis via apoptosis inhibition in colorectal cancers. Br J Cancer 2014; 110:164-71.
19. Wang F, Yuan JH, Wang SB, Yang F, Yuan SX, Ye C, et al. Oncofetal long noncoding RNA PVT1 promotes proliferation and stem cell-like property of hepatocellular carcinoma cells by stabilizing NOP2. Hepatology 2014; 60:1278-90.
20. Rong Kong, Erbao Zhang, Dandan Yin, Liang-hui You, Tong-peng Xu, Wen-ming Chen, et al. Long noncoding RNA PVT1 indicates a poor prognosis of gastric cancer and promotes cell proliferation through epigenetically regulating p15 and p16. Mol Cancer 2015; 14:82.
21. Yang YR, Zang SZ, Zhong CL, Li YX, Zhao SS, Feng XJ, et al. Increased expression of the lncRNA PVT1 promotes tumorigenesis in non-small cell lung cancer. Int J Clin Exp Pathol 7; 6929-35.
22. Sanchez-Palencia A, Gomez-Morales M, Gomez-Capilla JA, Pedraza V, Boyero L, Rosell R, et al.Gene expression profiling reveals novel biomarkers in nonsmall cell lung cancer. Int J Cancer 2011; 129:355-64.
23. Hou J, Aerts J, den Hamer B, van Ijcken W, den BakkerM, Riegman P, et al. Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PloS One 2010; 5:e10312.
24. Lu TP, Tsai MH, Lee JM, Hsu CP, Chen PC, Lin CW, et al. Identification of a novel biomarker, SEMA5A, for non-small cell lung carcinoma in nonsmoking women. Cancer Epidemiol Biomarkers Prev 2010; 19:2590-7.
25. Rousseaux S, DebernardiA, Jacquiau B, Vitte AL, Vesin A, Nagy-Mignotte H, et al. Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med 2013; 5:186ra66.
26. Harrow J, Frankish A, Gonzalez JM, Tapanari E, Diekhans M, Kokocinski F, et al. GENCODE: The reference human genome annotation for The ENCODE Project. Genome Res 2012; 22:1760-74.
27. Tarca AL, LauriaM, Unger M, Bilal E, Boue S, Kumar Dey K, et al. Strengths and limitations ofmicroarray-based phenotype prediction: lessons learned from the IMPROVER diagnostic signature challenge. Bioinformatics 2013; 29:2892-9.
28. Okayama H, Kohno T, Ishii Y, Shimada Y, Shiraishi K, Iwakawa R, et al. Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALKnegative lung adenocarcinomas. Cancer Res 2012; 72:100-11.
29. Liao WT, Wang X, Xu LH, Kong QL, Yu CP, Li MZ, et al. Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival. Cancer 2009; 115:1507-151.
30. Muppirala UK, Honavar VG, Dobbs D. Predicting RNA-protein interactions using only sequence information. BMC Bioinformatics 2011; 12:489.
31. Strazisar M, Mlakar V, Glavac D. LATS2 tumour specific mutations and down-regulation of the gene in non-small cell carcinoma. Lung Cancer 2009; 64:257-62.
32. Yao F, Liu H, Li Z, Zhong C, Fang W. Down-regulation of LATS2 in nonsmall cell lung cancer promoted the growth and motility of cancer cells. Tumour Biol 2015; 36:2049-57.
33. Sasaki H, Hikosaka Y, KawanoO, Yano M, Fujii Y. Hypermethylation of the large tumor suppressor genes in Japanese lung cancer. Oncol Lett 2010; 1:303-7.
34. Aylon Y, Michael D, Shmueli A, Yabuta N, Nojima H, Oren M. A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidization. Genes Dev 2006; 20:2687-700.
35. Zhang ZZ, Shen ZY, Shen YY, Xu J, Zhao EH, Wang M, et al. HOTAIR long noncoding RNA promotes gastric cancer metastasis through suppression of Poly r(C) Binding Protein (PCBP) 1. Mol Cancer Ther 2015; 14:1162-70.
36. Yu T, Bachman J, Lai ZC. Mutation analysis of large tumor suppressor genes LATS1 and LATS2 supports a tumor suppressor role in human cancer. Protein Cell 2015; 6:6-11.
37. Li J, Chen X, Ding X, Cheng Y, Zhao B, Lai ZC, et al. LATS2 suppresses oncogenic Wnt signaling by disrupting b-catenin/BCL9 interaction. Cell Rep 2013; 5:1650-63.
38. Murakami H, Mizuno T, Taniguchi T, Fujii M, Ishiguro F, Fukui T, et al. LATS2 is a tumor suppressor gene ofmalignantmesothelioma. Cancer Res 2011; 71:873-83.
39. Takahashi Y, Miyoshi Y, Takahata C, Irahara N, Taguchi T, Tamaki Y, et al. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res 2005; 11:1380-5.
40. Jiang Z, Li X, Hu J, Zhou W, Jiang Y, Li G, et al. Promoter hypermethylationmediated down-regulation of LATS1 and LATS2 in human astrocytoma. Neurosci Res 2006; 56:450-8.
41. Feng S, Pan W, Jin Y, Zheng J. MiR-25 promotes ovarian cancer proliferation and motility by targeting LATS2. Tumour Biol 2014; 35:12339-44.
42. Xia Y, Gao Y. MicroRNA-181b promotes ovarian cancer cell growth and invasion by targeting LATS2. Biochem Biophys Res Commun 2014; 447:446-51.
43. Fang L, Du WW, Yang W, Rutnam ZJ, Peng C, Li H, et al. MiR-93 enhances angiogenesis and metastasis by targeting LATS2. Cell Cycle 2012; 11:4352-65.
44. Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell 2009; 136:629-41.
45. Ma MZ, Chu BF, Zhang Y, Weng MZ, Qin YY, Gong W, et al. Long noncodingRNACCAT1 promotes gallbladder cancer development via negative modulation of miRNA-218-5p. Cell Death Dis 2015; 6:e1583.
46. Cao C, Sun J, Zhang D, Guo X, Xie L, Li X, et al. The long intergenic noncoding RNA UFC1, a target of microRNA 34a, interacts with the mRNA stabilizing protein HuR to increase levels of b-Catenin in HCC cells. Gastroenterology 2015; 148:415-26.e18.